Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig

Transplantation

Volumn 67, Issue 12, 1999, Pages 1607-1613

  Feng, Sandy ^a,b   Quickel, Robert R ^c   Hollister Lock, Jennifer ^c   McLeod, Matthew ^a   Bonner Weir, Susan ^c   Mulligan, Richard C ^a   Weir, Gordon C ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G2B; STREPTOZOCIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FLUORESCENCE ACTIVATED CELL SORTER; GRAFT SURVIVAL; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; XENOGRAFT;

ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; BETA-GALACTOSIDASE; GENE EXPRESSION; GRAFT SURVIVAL; IMMUNOCONJUGATES; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; ISLETS OF LANGERHANS TRANSPLANTATION; LAC OPERON; MALE; MICE; MICE, INBRED STRAINS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032975091     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199906270-00016     Document Type: Article

References (43)

1. Qin L, Chavin KD, Ding Y, et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model: immunosuppression with TGF-beta 1 or vIL-10. Transplantation 1997; 59: 809.
2. Drazan KE, Wu L, Olthoff KM, Jurim O, Busuttil RW, Shaked A. Transduction of hepatic allografts achieves local levels of viral IL-10 which suppress alloreactivity in vitro. J Surg Res 1995; 59: 219.
3. Drazan KE, Olthoff KM, Wu L, Shen XD, Gelman A, Shaked A. Adenovirus-mediated gene transfer in the transplant setting: early events after orthotopic transplantation of liver allografts expressing TGF-beta. Transplantation 1996; 62: 1080.
4. Deng S, Ketchum RJ, Kucher Weber TM, Shaked A, Naji A, Brayman KL. IL-10 and TGF-beta gene transfer for xenogeneic islet transplantation: comparison of effect in concordant vs discordant combination. Transplant Proc 1997; 29: 2204.
5. Olthoff KM, Judge TA, Gelman AE, et al. Adenovirus-mediated gene transfer into cold-preserved liver allografts: survival pattern and unresponsiveness following transduction with CTLA4Ig. Nature Med 1998; 4: 194.
6. Gimmi CD, Freeman GJ, Morimoto C, Nadler LM. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991; 88: 6575.
7. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
8. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065.
9. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586.
10. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61: 4.
11. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789.
12. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792.
13. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
14. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
15. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869.
16. Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995; 155: 1165.
17. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842.
18. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456.
19. Green M, Wold WSM. Human adenoviruses: growth purification, and transfection assay. Methods Enzymol 1979; 58: 425.
20. Meisenhelder J, Hunter T. Radioactive protein labelling techniques. Nature 1988; 335: 120.
21. Sonderbye L, Feng S, Yacoubian S, et al. In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus mediated gene transduction. Exp Clin Immunogenet 1998; 15: 100.
22. Gotoh M, Maki T, Satomi S, Porter J, Monaco AP. Immunological characteristics of purified pancreatic islet grafts. Transplantation 1986; 42: 387.
23. Davalli A, Ogawa Y, Scaglia L, Wu YJ, Hollister J, Bonner-Weir S, Weir GC. Function, mass and replication of porcine and rat islets transplanted into diabetic nude mice. Diabetes 1995; 44: 104.
24. Deng S, Yang T, Kucher M, et al. Local blockade of costimulatory signal by transfection of CTLA4-Ig to islets prolongs islet xenograft survival [Abstract]. Acta Diabetologia 1997; 34: 115.
25. Gainer AL, Korbutt GS, Rajotte RV, Warnock GL, Elliott JF. Expression of CTLA4-Ig by biolistically transfected mouse islets promotes islet allograft survival. Transplantation 1997; 63: 1017.
26. Chahine AA, Yu M, McKernan MM, Stoechert C, Lau HT. Immunomodulation of pancreatic islet allografts in mice with CTLA4Ig secreting muscle cells. Transplantation 1995; 59: 1313.
27. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407.
28. + CTLs in vivo. J Immunol 1995; 155: 2564.
29. Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370.
30. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401.
31. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004.
32. Kay MA, Holterman AX, Meuse L, et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nature Genet 1995; 11: 191.
33. Kay MA, Meuse L, Gown AM, et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686.
34. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
35. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
36. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994; 5: 1217.
37. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196.
38. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet 1994; 7: 362.
39. Armentano DC, Sookdeo CC, Hehir KM, et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995; 6: 1343.
40. Krougliak V, Graham FL. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995; 6: 1575.
41. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263.
42. Blomer UL, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71: 6641.
43. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306.